Overview

A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Duloxetine Hydrochloride